PREVAIL
A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) Who Are Not Adequately Controlled Despite Maximally Tolerated Lipid-Modifying Therapies
- Stadium
- followup
- Middel
- Obicetrapib
- Populatie
- ASCVD
- Fase
- III
- First Patient In
- 20 juni 2022
- Last Patient In
- 30 april 2024
- Last Patient Last Visit
- 1 november 2026
National Lead
dr. mr. A.J.M. Oude Ophuis
Cardioloog
Studiedirecteur
dr. C. van Ofwegen-Hanekamp
Cardioloog
Contact Kantoor
